EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

NANETS Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumors

Hagen Kennecke iD, Ebrahim Delpassand, Seth Felder, Ferga Gleeson, Julie Hallet iD, David Horowitz, Martin Hyrcza, Bryson W Katona, Maria Kiely, Michelle Kim, Nadine Mallak, Vicky Parkins und 2 weitere

Endocrine-Related Cancer · 2026

DOI: 10.1530/erc-25-0303 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Endocrine-Related Cancer, 2026. Verfasst von Hagen Kennecke und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology and Hematology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Rectal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Unrestricted funding support from NANETS operations..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Well-differentiated rectal neuroendocrine tumors (rNETs) are among the most common NETs and account for approximately 12–27% of all gastrointestinal NETs in North America. Significant discrepancies persist in the management of NETs regarding surveillance strategies, staging modalities, high-risk features, and criteria for surgical intervention. This guideline updates current practices of stage I–III rectal NETs with the utilization of GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) methodology and Delphi method of consensus among leading experts in the North American region. We found that several technological advances, such as 68Ga- or 64Cu-DOTATATE SSTR PET/CT, and broad adoption of pelvic MRI have improved staging of rNETs, along with modified endoscopic mucosal and submucosal resection and full-thickness excision techniques that demonstrate efficacy and safety for resection. Pivotal long-term outcome studies provide insight into i) risk factors for regional lymph node metastasis, ii) the impact of R1 excision (endoscopic), iii) best practices for intermediate-sized rNETs (11–20 mm), and iv) risk in small rNETs (≤10 mm). Recommendations were developed upon evidence-based conclusions from the GRADE review to define the role of baseline staging with MRI, advanced endoscopy, and transanal endoscopic surgical methods appropriate for T1 rNETs, the role of salvage therapy in cases of R1 resection, and the consideration of pathologic variables to direct definitive treatment and surveillance. We conclude that advances in screening programs and imaging allow for improved detection and staging of rNETs, while long-term outcome studies can better direct patients toward evidence-based treatment management and rectal organ preservation through less radical resection methods.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsRectal NeoplasmsHumansNeoplasm Staging

Stichwörter der Autor:innen

NANETSfollow-upguidelinesneuroendocrinerectalrectal NETstaging

Autor:innen und Institutionen

  • Division of Medical Oncology and Hematology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.
  • Department of Nuclear Medicine, Excel Diagnostics & Nuclear Oncology Center, Houston, Texas, USA.
  • Department of Gastrointestinal Surgical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
  • Department of Gastroenterology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Surgery, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Department of Radiation Oncology, Columbia University Irving Medical Center, New York, New York, USA.

ORCID-Profile: Hagen Kennecke, Julie Hallet

Förderung

  • Unrestricted funding support from NANETS operations.

Zitieren

APA

Kennecke, H., Delpassand, E., Felder, S., Gleeson, F., Hallet, J., Horowitz, D., Hyrcza, M., Katona, B. W., Kiely, M., Kim, M., Mallak, N., Parkins, V., Varma, M. G., & Pasieka, J. (2026). NANETS Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumors. Endocrine-Related Cancer. https://doi.org/10.1530/erc-25-0303

Vancouver

Kennecke H, Delpassand E, Felder S, Gleeson F, Hallet J, Horowitz D, et al. NANETS Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumors. Endocrine-Related Cancer. 2026. doi:10.1530/erc-25-0303

BibTeX
@article{Kennecke2026,
  author = {Kennecke, Hagen and Delpassand, Ebrahim and Felder, Seth and Gleeson, Ferga and Hallet, Julie and Horowitz, David and Hyrcza, Martin and Katona, Bryson W and Kiely, Maria and Kim, Michelle and Mallak, Nadine and Parkins, Vicky and Varma, Madhulika G and Pasieka, Janice},
  title = {NANETS Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumors},
  journal = {Endocrine-Related Cancer},
  year = {2026},
  doi = {10.1530/erc-25-0303}
}
Kostenlos starten →